FI960006A - Liukoisten fibriinipolymeerien immunoanalyysi - Google Patents
Liukoisten fibriinipolymeerien immunoanalyysi Download PDFInfo
- Publication number
- FI960006A FI960006A FI960006A FI960006A FI960006A FI 960006 A FI960006 A FI 960006A FI 960006 A FI960006 A FI 960006A FI 960006 A FI960006 A FI 960006A FI 960006 A FI960006 A FI 960006A
- Authority
- FI
- Finland
- Prior art keywords
- immunoassay
- soluble fibrin
- fibrin polymers
- polymers
- soluble
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6815—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9723—Urokinase
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/972—Modified antibody, e.g. hybrid, bifunctional
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/086,423 US5453359A (en) | 1988-06-13 | 1993-07-02 | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
PCT/US1994/007087 WO1995001568A1 (en) | 1993-07-02 | 1994-06-22 | Immunoassay for soluble fibrin polymers |
Publications (2)
Publication Number | Publication Date |
---|---|
FI960006A0 FI960006A0 (fi) | 1996-01-02 |
FI960006A true FI960006A (fi) | 1996-03-01 |
Family
ID=22198474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI960006A FI960006A (fi) | 1993-07-02 | 1996-01-02 | Liukoisten fibriinipolymeerien immunoanalyysi |
Country Status (18)
Country | Link |
---|---|
US (7) | US5453359A (fi) |
EP (1) | EP0706656A4 (fi) |
JP (1) | JPH08512136A (fi) |
KR (1) | KR100291368B1 (fi) |
CN (1) | CN1129984A (fi) |
AU (1) | AU688345B2 (fi) |
BR (1) | BR9406944A (fi) |
CA (1) | CA2166386A1 (fi) |
CZ (1) | CZ696A3 (fi) |
FI (1) | FI960006A (fi) |
HU (1) | HUT73804A (fi) |
NO (1) | NO955314L (fi) |
NZ (1) | NZ268785A (fi) |
PL (1) | PL178003B1 (fi) |
RU (1) | RU2173347C2 (fi) |
SG (1) | SG50674A1 (fi) |
SK (1) | SK596A3 (fi) |
WO (1) | WO1995001568A1 (fi) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5453359A (en) * | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
DE69435072T2 (de) * | 1993-11-02 | 2009-01-29 | Mitsubishi Kagaku Iatron, Inc. | Antikörper gegen menschliches lösliches fibrin, hybridome, die sie produzieren und immunmessverfahren |
EP0759762A4 (en) * | 1994-05-02 | 1999-09-01 | Squibb & Sons Inc | RECOMBINANT FIBRIN CHAINS, FIBRIN AND FIBRIN APPROVED |
US6627404B1 (en) * | 1995-04-18 | 2003-09-30 | Biosite, Inc. | Methods for improving the recovery of troponin I and T in membranes, filters and vessels |
US6991907B1 (en) * | 1995-04-18 | 2006-01-31 | Biosite, Inc. | Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays |
WO1996040986A1 (en) * | 1995-06-07 | 1996-12-19 | American Biogenetic Sciences, Inc. | Calibrator for use in a soluble fibrin assay |
US5817768A (en) * | 1995-06-07 | 1998-10-06 | The New York Blood Center, Inc. | Monospecific antibodies against a subunit of fibrinogen |
JP3742675B2 (ja) * | 1995-06-28 | 2006-02-08 | 東菱薬品工業株式会社 | 虚血−再灌流障害の予防および治療薬 |
AU6398596A (en) * | 1995-06-30 | 1997-02-05 | American Biogenetic Sciences, Inc. | Method of producing fibrin-specific antibodies using soluble fibrin polymers as an immunogen |
US7381407B1 (en) | 1996-03-25 | 2008-06-03 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6962981B1 (en) * | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
CA2251160A1 (en) * | 1996-04-09 | 1997-10-16 | Kerry D. O'mara | Plate for reaction system |
US5840256A (en) * | 1996-04-09 | 1998-11-24 | David Sarnoff Research Center Inc. | Plate for reaction system |
US5938595A (en) * | 1996-05-24 | 1999-08-17 | The Regents Of The University Of California | Fiber optic D dimer biosensor |
KR100222292B1 (ko) * | 1997-06-18 | 1999-10-01 | 허일섭 | 피브린 단량체를 이용한 혈액 응고 제 13인자의활성 측정방법 |
US6727102B1 (en) * | 1997-06-20 | 2004-04-27 | Leuven Research & Development Vzw | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins |
JP4142747B2 (ja) * | 1997-06-24 | 2008-09-03 | 日水製薬株式会社 | 抗ヒトフィブリンモノマー特異的モノクローナル抗体、該モノクローナル抗体の製造方法、ハイブリドーマ及び免疫学的測定方法 |
ES2395693T3 (es) | 1998-06-12 | 2013-02-14 | Genentech, Inc. | Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la fabricación de los mismos |
US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
ATE515229T1 (de) | 1999-11-08 | 2011-07-15 | Univ Florida | Vorrichtung zur erfassung eines markers zur überwachung der befolgung einer arzneimitteltherapie |
FR2813395B1 (fr) * | 2000-08-28 | 2003-01-24 | Stago Diagnostica | Methode de dosage in vitro de la fibrine soluble par generation de produits de degradation specifiques |
US20020043389A1 (en) * | 2000-09-29 | 2002-04-18 | Selvarajan Murugan | Virtual gate design for thin packages |
US7104963B2 (en) * | 2002-01-22 | 2006-09-12 | University Of Florida Research Foundation, Inc. | Method and apparatus for monitoring intravenous (IV) drug concentration using exhaled breath |
US20050054942A1 (en) * | 2002-01-22 | 2005-03-10 | Melker Richard J. | System and method for therapeutic drug monitoring |
US6981947B2 (en) * | 2002-01-22 | 2006-01-03 | University Of Florida Research Foundation, Inc. | Method and apparatus for monitoring respiratory gases during anesthesia |
US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
US20040203083A1 (en) * | 2001-04-13 | 2004-10-14 | Biosite, Inc. | Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases |
US20040121350A1 (en) * | 2002-12-24 | 2004-06-24 | Biosite Incorporated | System and method for identifying a panel of indicators |
US20030199000A1 (en) * | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040176914A1 (en) * | 2001-04-13 | 2004-09-09 | Biosite Incorporated | Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
ATE458199T1 (de) | 2001-05-04 | 2010-03-15 | Biosite Inc | Diagnostische marker der akuten koronaren syndrome und ihre verwendungen |
US7052854B2 (en) | 2001-05-23 | 2006-05-30 | University Of Florida Research Foundation, Inc. | Application of nanotechnology and sensor technologies for ex-vivo diagnostics |
US7052468B2 (en) | 2001-05-24 | 2006-05-30 | University Of Florida Research Foundation, Inc. | Method and apparatus for detecting environmental smoke exposure |
US7608406B2 (en) * | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20070167853A1 (en) | 2002-01-22 | 2007-07-19 | Melker Richard J | System and method for monitoring health using exhaled breath |
US20040110687A1 (en) * | 2002-02-26 | 2004-06-10 | Roland Buelow | Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy |
WO2005033327A2 (en) * | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
US20050181451A1 (en) * | 2004-02-12 | 2005-08-18 | Bates Harold M. | Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants |
US20080050832A1 (en) * | 2004-12-23 | 2008-02-28 | Buechler Kenneth F | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
WO2006070776A1 (ja) * | 2004-12-28 | 2006-07-06 | Daiichi Pure Chemicals Co., Ltd. | 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法 |
JP5249587B2 (ja) * | 2005-02-18 | 2013-07-31 | メダレックス, インク. | フコシル残基を欠く前立腺特異的膜抗原(psma)に対するモノクローナル抗体 |
EP2005168A4 (en) * | 2006-03-09 | 2009-05-20 | Biosite Inc | METHODS AND COMPOSITIONS FOR DIAGNOSING DISEASES OF AORTA |
US20080118924A1 (en) * | 2006-05-26 | 2008-05-22 | Buechler Kenneth F | Use of natriuretic peptides as diagnostic and prognostic indicators in vascular diseases |
EP1870712A1 (en) * | 2006-06-20 | 2007-12-26 | Universität Bern | Method for assaying a thrombotic event |
US7914460B2 (en) | 2006-08-15 | 2011-03-29 | University Of Florida Research Foundation, Inc. | Condensate glucose analyzer |
US7740801B2 (en) * | 2006-10-31 | 2010-06-22 | Lifescan Scotland Limited | System for determination of an analyte in a bodily fluid sample that includes an electroluminescent component |
WO2008060607A2 (en) | 2006-11-14 | 2008-05-22 | Biosite Incorporated | Methods and compositions for monitoring and risk prediction in cardiorenal syndrome |
US8524462B2 (en) * | 2006-11-14 | 2013-09-03 | Alere San Diego, Inc. | Methods and compositions for diagnosis and prognosis of renal artery stenosis |
US20090004755A1 (en) * | 2007-03-23 | 2009-01-01 | Biosite, Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US8221995B2 (en) * | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
EP2753935A1 (en) * | 2011-09-07 | 2014-07-16 | Genway Biotech, Inc. | Diagnostic assay to predict cardiovascular risk |
WO2013144215A1 (de) * | 2012-03-29 | 2013-10-03 | Roche Diagnostics Gmbh | Verfahren zur schulung von personal in der qualitätskontrolle |
US9754505B2 (en) | 2012-03-29 | 2017-09-05 | F. Hoffmann-La Roche Ag | Method for training staff in quality control |
CN104379169A (zh) | 2012-08-14 | 2015-02-25 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
KR102356017B1 (ko) | 2012-12-13 | 2022-01-27 | 이뮤노메딕스, 인코오포레이티드 | 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약 |
CN103954758A (zh) * | 2014-05-15 | 2014-07-30 | 海南世济医学技术有限公司 | 一种用于纤维蛋白和纤维蛋白原及其降解产物的检测方法和试剂盒 |
US11143659B2 (en) | 2015-01-27 | 2021-10-12 | Arterez, Inc. | Biomarkers of vascular disease |
WO2020092531A1 (en) * | 2018-10-30 | 2020-05-07 | The Research Institute At Nationwide Children's Hospital | Factor xiii immunoassay |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1362776A (en) * | 1970-07-17 | 1974-08-07 | Wellcome Found | Immunological reagent |
DE2532151C3 (de) * | 1975-07-18 | 1979-06-13 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Antisenim zur quantitativen Bestimmung der Abbauprodukte des Fibrins und Fibrinogen« und Verfahren zu seiner Herstellung |
US4036945A (en) * | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4421735A (en) * | 1980-04-17 | 1983-12-20 | The Massachusetts General Hospital | Radiolabeled diagnostic compositions and method for making the same |
US4355023A (en) * | 1980-09-30 | 1982-10-19 | The Massachusetts General Hospital | Antibody fragment compositions and process |
US4438209A (en) * | 1981-07-17 | 1984-03-20 | Mallinckrodt, Inc. | Radioimmunoassay for fibrinopeptide A |
US4550086A (en) * | 1983-02-16 | 1985-10-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that recognize human T cells |
AU572125B2 (en) * | 1983-03-17 | 1988-05-05 | Mabco Limited | Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses |
US4722903A (en) * | 1983-11-14 | 1988-02-02 | New York Blood Center, Inc. | Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II |
US4927916A (en) * | 1984-04-23 | 1990-05-22 | The General Hospital Corporation | Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides |
US5256413A (en) * | 1985-01-08 | 1993-10-26 | The General Hospital Corporation | Method and use for site-specific activation of substances |
AU595173B2 (en) * | 1985-01-08 | 1990-03-29 | General Hospital Corporation, The | Method and use for site-specific activation of substances |
NL8501682A (nl) * | 1985-06-11 | 1987-01-02 | Tno | Nieuw, uit bloed geisoleerd eiwit, werkwijze ter bereiding van dit eiwit, antilichamen tegen het nieuwe eiwit en farmaceutische preparaten, die het eiwit of de antilichamen bevatten. |
US4916070A (en) * | 1986-04-14 | 1990-04-10 | The General Hospital Corporation | Fibrin-specific antibodies and method of screening for the antibodies |
US5453359A (en) * | 1988-06-13 | 1995-09-26 | American Biogenetic Sciences, Inc. | Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers |
US5120834A (en) * | 1988-06-13 | 1992-06-09 | American Biogenetic Sciences, Inc. | Fibrin-specific monoclonal antibody |
US5223410A (en) * | 1988-06-13 | 1993-06-29 | American Biogenetic Sciences, Inc. | Method for production of antibodies utilizing an antigen-free animal |
US5091512A (en) * | 1988-06-13 | 1992-02-25 | American Biogenetic Sciences, Inc. | Fibrinogen-specific monoclonal antibody |
IE67430B1 (en) * | 1988-06-24 | 1996-04-03 | Res Corp Technologies Inc | Assay for soluble crosslinked fibrin polymers |
US5487892A (en) * | 1994-02-24 | 1996-01-30 | American Biogenetic Sciences, Inc. | Method for treating thrombotic disease using a fibrin specific monoclonal antibody |
-
1993
- 1993-07-02 US US08/086,423 patent/US5453359A/en not_active Expired - Lifetime
-
1994
- 1994-06-22 AU AU72122/94A patent/AU688345B2/en not_active Ceased
- 1994-06-22 CA CA002166386A patent/CA2166386A1/en not_active Abandoned
- 1994-06-22 BR BR9406944A patent/BR9406944A/pt not_active Application Discontinuation
- 1994-06-22 HU HU9503875A patent/HUT73804A/hu unknown
- 1994-06-22 RU RU96103363/13A patent/RU2173347C2/ru not_active IP Right Cessation
- 1994-06-22 SK SK5-96A patent/SK596A3/sk unknown
- 1994-06-22 WO PCT/US1994/007087 patent/WO1995001568A1/en not_active Application Discontinuation
- 1994-06-22 CN CN94193177A patent/CN1129984A/zh active Pending
- 1994-06-22 SG SG1996008390A patent/SG50674A1/en unknown
- 1994-06-22 EP EP94921364A patent/EP0706656A4/en not_active Withdrawn
- 1994-06-22 NZ NZ268785A patent/NZ268785A/en unknown
- 1994-06-22 JP JP7503560A patent/JPH08512136A/ja active Pending
- 1994-06-22 PL PL94312384A patent/PL178003B1/pl unknown
- 1994-06-22 KR KR1019950705946A patent/KR100291368B1/ko not_active IP Right Cessation
- 1994-06-22 CZ CZ966A patent/CZ696A3/cs unknown
-
1995
- 1995-06-02 US US08/460,698 patent/US5721122A/en not_active Expired - Lifetime
- 1995-06-02 US US08/459,596 patent/US5843690A/en not_active Expired - Lifetime
- 1995-06-02 US US08/460,702 patent/US5723126A/en not_active Expired - Lifetime
- 1995-12-27 NO NO955314A patent/NO955314L/no not_active Application Discontinuation
-
1996
- 1996-01-02 FI FI960006A patent/FI960006A/fi unknown
-
1998
- 1998-03-19 US US09/044,063 patent/US5871737A/en not_active Expired - Fee Related
- 1998-12-09 US US09/207,913 patent/US6187593B1/en not_active Expired - Fee Related
-
2000
- 2000-11-28 US US09/724,404 patent/US6294173B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR960703468A (ko) | 1996-08-17 |
CA2166386A1 (en) | 1995-01-12 |
US5723126A (en) | 1998-03-03 |
US5453359A (en) | 1995-09-26 |
US5843690A (en) | 1998-12-01 |
CZ696A3 (en) | 1996-07-17 |
EP0706656A1 (en) | 1996-04-17 |
SK596A3 (en) | 1996-05-08 |
EP0706656A4 (en) | 1998-05-20 |
NO955314L (no) | 1996-02-20 |
CN1129984A (zh) | 1996-08-28 |
HU9503875D0 (en) | 1996-02-28 |
US6187593B1 (en) | 2001-02-13 |
US5871737A (en) | 1999-02-16 |
AU688345B2 (en) | 1998-03-12 |
PL178003B1 (pl) | 2000-02-29 |
FI960006A0 (fi) | 1996-01-02 |
PL312384A1 (en) | 1996-04-15 |
NO955314D0 (no) | 1995-12-27 |
BR9406944A (pt) | 1996-08-06 |
KR100291368B1 (ko) | 2002-02-01 |
US6294173B1 (en) | 2001-09-25 |
US5721122A (en) | 1998-02-24 |
WO1995001568A1 (en) | 1995-01-12 |
NZ268785A (en) | 1997-12-19 |
AU7212294A (en) | 1995-01-24 |
HUT73804A (en) | 1996-09-30 |
SG50674A1 (en) | 1998-07-20 |
RU2173347C2 (ru) | 2001-09-10 |
JPH08512136A (ja) | 1996-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI960006A (fi) | Liukoisten fibriinipolymeerien immunoanalyysi | |
DE69431077D1 (de) | Zusammensetzung von Propylen-Polymeren | |
DK145493D0 (da) | Antistof | |
DE69321655D1 (de) | Zweianalytenimmunoassay | |
BR9407549A (pt) | Absorvente feminino | |
FI945857A0 (fi) | Immunomääritys | |
DE69429509D1 (de) | Tampon | |
DE59407120D1 (de) | Drehtisch mit schrittantrieb | |
DE69425384D1 (de) | Granulieren von schlacke | |
FI953916A0 (fi) | Fibrinogeenireseptoriantagonisteja | |
DE69423801D1 (de) | Frequenzumsetzer | |
DK134088D0 (da) | Mobilt vejeanlaeg | |
DK26189D0 (da) | Organoborsilazan-polymere | |
DE59304127D1 (de) | Signalgeber | |
DK36193D0 (da) | Fremgangsmaade | |
BR9006517A (pt) | Polimeros e compostos | |
DK77793D0 (da) | Assay | |
KR910010533U (ko) | 새 쫒는 기구 | |
KR940027738U (ko) | 신호 변환장치 | |
KR950012338U (ko) | 시보장치 | |
DK101993D0 (da) | Spaerfag | |
NO930190D0 (no) | Frekvens-vaeskenivaamaaler | |
KR950013900U (ko) | 방향 지시등 자동 소등 장치 | |
KR950012229U (ko) | 운반구를 겸한 냉장고용 조정족 | |
SE9302779L (sv) | Sving koordinatorn |